CLBT — Cellebrite DI Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.15bn
- $1.89bn
- $325.11m
- 77
- 21
- 97
- 71
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1.88 | 5.78 | 71.4 | 121 | -81.1 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 12.8 | 7.96 | -61.4 | -104 | 130 |
Other Non-Cash Items | |||||
Changes in Working Capital | 2.84 | 49.7 | 20.7 | -2.82 | 38.5 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 16.1 | 66.5 | 36.1 | 20.6 | 102 |
Capital Expenditures | -6.21 | -6.18 | -8.11 | -9.09 | -7.92 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -40.5 | -0.268 | 53.3 | -82.1 | -14.6 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -46.7 | -6.45 | 45.2 | -91.2 | -22.5 |
Financing Cash Flow Items | 0 | 0 | 29.3 | 0 | 0 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 75.5 | -8.59 | -68.4 | 14 | 21.8 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 44.9 | 52.2 | 12.1 | -58.3 | 102 |